Voyager Therapeutics Net Income 2014-2022 | VYGR

Voyager Therapeutics net income from 2014 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Voyager Therapeutics Annual Net Income
(Millions of US $)
2021 $-71
2020 $37
2019 $-44
2018 $-88
2017 $-71
2016 $-40
2015 $-38
2014 $-18
2013 $-4
Voyager Therapeutics Quarterly Net Income
(Millions of US $)
2022-03-31 $-21
2021-12-31 $6
2021-09-30 $-25
2021-06-30 $-30
2021-03-31 $-22
2020-12-31 $-16
2020-09-30 $86
2020-06-30 $-9
2020-03-31 $-24
2019-12-31 $-13
2019-09-30 $-15
2019-06-30 $11
2019-03-31 $-27
2018-12-31 $-23
2018-09-30 $-20
2018-06-30 $-26
2018-03-31 $-20
2017-12-31 $-12
2017-09-30 $-23
2017-06-30 $-19
2017-03-31 $-17
2016-12-31 $-15
2016-09-30 $-9
2016-06-30 $-9
2016-03-31 $-7
2015-12-31 $-9
2015-09-30 $-7
2015-06-30 $-7
2015-03-31 $-16
2014-12-31 $-5
2014-09-30 $-4
2014-06-30 $-5
2014-03-31 $-3
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.234B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00